Opaleye Management Inc. Nurix Therapeutics, Inc. Transaction History
Opaleye Management Inc.
- $364 Million
- Q1 2025
A detailed history of Opaleye Management Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 115,000 shares of NRIX stock, worth $1.4 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
115,000
Previous 378,500
69.62%
Holding current value
$1.4 Million
Previous $7.13 Million
80.84%
% of portfolio
0.38%
Previous 1.4%
Shares
5 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$82.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$66.8 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$53.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$49.2 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$48.3 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $572M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...